Trisomy 18

When deciding whether traditional prenatal screening for fetal disorders including Edwards' Syndrome (trisomy 18) is worth the potential complications, the options and risks can be difficult to discern. Luckily, there are now safer alternatives to amniocentesis that offer close to 100% accurate detection of trisomy 18 and related disorders, including Down Syndrome. The innovative, entirely non-invasive prenatal screening procedure developed by Eurofins Biomnis is a simple genetic test for pregnant women at risk for trisomy 13, 18, and 21. These easy-to-administer, reliable and safe NIPT tests quickly and effectively detect all three of these common chromosomal disorders, and offer expectant parents true peace of mind when compared with invasive counterparts.

Available starting at the tenth week of pregnancy, the Eurofins Biomnis NIPT trisomy 18 test offers effective fetal detection, detecting conditions including Edwards' Syndrome and Fetal Patau Syndrome with an almost 100% rate of accuracy. The genetic test is performed by drawing a maternal blood sample. Aside from maternal DNA, maternal blood contains fetal DNA originating from the placenta. The identification of fetal DNA in this sample, in tandem with a new technology capable of counting all genetic material sequences within it, allows for an extremely accurate detection of abnormalities. Opting for an NIPT trisomy 18 test may allow you to limit or entirely forgo invasive screening procedures.

While patients may assume that trisomy 18 screening is necessarily a complicated medical procedure, this innovative non-invasive prenatal diagnosis tool is remarkably simple to prescribe and administer. The procedure can be prescribed by your healthcare provider, and you can have the simple blood test taken at your physician's office or at aEurofins Biomnis partner laboratory. It can be taken early in your pregnancy, after only 10 weeks of pregnancy. With results of the blood test generally available after 7 working days, NIPT by Eurofins Biomnis is an efficient, safe, and remarkably accurate way to undergo trisomy 18 invasive screening. It has been found to reduce unnecessary invasive sampling by up to 95%.